Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EQUIDYNE CORP: IJX (AMEX) -- Ignore unavailable to you. Want to Upgrade?

To: dgrebles who wrote (159)	5/19/2001 1:05:11 AM
From: Skywatcher	Respond to of 179

Having no idea what is involved with the insulin injection or inhalation....I will leave this to you! You are the man as far as I'm concerned on this subject so...holding on and betting more on the come. chris

To: dgrebles who wrote (159)	7/3/2001 11:40:30 AM
From: Skywatcher	Respond to of 179

SAN DIEGO, Calif. (Dow Jones)--Equidyne Corp. (IJX) received Food and Drug Administration approval for its Injex single-use disposable needle-free drug delivery system. In a press release Monday, the company said it is in talks with pharmaceutical manufacturers and government agencies about possible applications for the product. Potential applications include short-term injectable drug therapies administered by patients at home, as well as some subcutaneous vaccines. Equidyne said it will start production of the product in the U.S. when it signs a license and supply agreement. Shares of Equidyne recently traded at $2.04, up 33 cents, or 19.3%, on Nasdaq volume of 36,900 shares. Average daily volume is 23,906 shares. Equidyne makes needle-free drug delivery systems for subcutaneous and intramuscular injections. -Karen M. Chow; Dow Jones Newswires; 201-938-5400 Now for the REVENUES!!!! without them we are going nowhere... chris

To: dgrebles who wrote (159)	7/13/2001 10:15:47 AM
From: Skywatcher	Respond to of 179

Equidyne Corporation and Rite Aid Expand Their Retail Marketing Partnership Equidyne and Rite Aid Corporation to Promote INJEX(TM) Directly to Customers with Diabetes Through Its Retail Pharmacies Nationwide SAN DIEGO and CAMP HILL, Pa.--(BW HealthWire)--July 13, 2001-- EQUIDYNE CORPORATION (AMEX:IJX - news) announced today it has expanded its marketing agreement with Rite Aid Corporation (NYSE:RAD - news), (PCX:RAD) to include ``direct-to-consumer'' promotions through the national pharmacy chain's 3,600 neighborhood stores in 30 states relating to the INJEX(TM) System. Additionally, Equidyne representatives have been working with Rite Aid at the local level scheduling patient awareness events to educate people with diabetes about the benefits of using INJEX(TM) for insulin administration. Several events have been held throughout the country and more are scheduled over the next several months. J. Randall Nelson, Chairman and Chief Executive Officer of Equidyne, stated, ``We have been extremely pleased with our association with Rite Aid and this expansion of our relationship will accelerate Equidyne's consumer-oriented marketing strategy. Extensive focus group research with both doctors and consumers show a pent-up demand for information about the INJEX(TM) needle-free devise and how it can be used to deliver insulin. People with diabetes want to know where to obtain it and how to use it, and health care professionals are willing to prescribe and train patients in the proper use of INJEX(TM). This new partnership with Rite Aid will help us reach more customers who can benefit from the INJEX(TM) System.'' ``We are excited about working with Equidyne to increase consumer awareness of the INJEX(TM) products, and providing our insulin customers with leading edge insulin delivery products,'' said Greg Drew, Rite Aid Vice President, Pharmacy Health Services. Gotta keep up the momemtum here...down and out for a few with the rest of the bio industry. looking for a healthy rebound. CC

To: dgrebles who wrote (159)	7/20/2001 9:05:14 AM
From: Skywatcher	Respond to of 179

This may lead the way,but major disappointment that the So Cal Company ABT didn't go with IJX Weston Medical and Abbott Laboratories Announced Option and Licensing Agreement for Novel Needlefree Injection Technology PETERBOROUGH, England, and ABBOTT PARK, Ill., July 20 /PRNewswire/ -- Weston Medical Group plc (LSE: WMG) and Abbott Laboratories (NYSE: ABT - news) announced today that they have entered into an exclusive, world-wide option and licensing agreement for the evaluation of Weston Medical's Intraject® needlefree drug delivery technology. Weston and Abbott will conduct joint studies to evaluate the Intraject technology for potential use with appropriate compounds in Abbott's pharmaceutical pipeline. If Abbott exercises its option, Abbott would have an exclusive right to utilise the Intraject technology for up to eleven therapeutic targets throughout the next 10 years. The potential annual peak sales for clinical candidates that may be appropriate for use with the technology are estimated to be in excess of 500 million U.S. dollars. Under the terms of the agreement, Weston Medical would receive upfront fees, milestone payments and royalties on the combined sales value of the drug plus the Intraject device. Financial terms of the agreement were not disclosed.

To: dgrebles who wrote (159)	10/3/2001 9:37:58 PM
From: Skywatcher	Respond to of 179

Well here we are...down where I have never even seen the stock before...so what do I do....BUY at .75 and one last good HUNK of the stuff...that's it....better make it from here. CC

To: dgrebles who wrote (159)	10/3/2001 9:39:31 PM
From: Skywatcher	Respond to of 179

CVS is supporting the product on the wesite very well.... cvs.com It's time to GET OUT THE WORD....damn, the product is as good as they get... At least we need to have point of purchase signs and demos at the pharmacies so that those millions buying the needles and insulin get the word that there is an alternative...and a GREAT alternative CC

To: dgrebles who wrote (159)	10/11/2001 12:05:17 PM
From: Skywatcher	Respond to of 179

Equidyne to Distribute INJEX Through 250 Stop & Shop Pharmacies SAN DIEGO, Calif.--(BW HealthWire)--Oct. 11, 2001--EQUIDYNE CORPORATION (AMEX:IJX - news) announced today that the company has finalized an agreement with Royal Ahold NV and its subsidiary, the Stop & Shop Supermarket Company, to distribute and co-market the INJEX(TM) Needle-Free Drug Delivery System developed and manufactured by Equidyne, through approximately 250 Stop & Shop stores located throughout five states. Stop & Shop is the largest food retailer in New England, employing more than 60,000 associates and operating more than 319 stores throughout Connecticut, Massachusetts, New York, New Jersey and Rhode Island. Its parent company, Royal Ahold NV, based in the Netherlands, is one of the largest food retailers in the world with supermarket companies in the United States, Europe, Latin America and Asia and annual sales of US$35 billion. ``This agreement represents a major step toward expanding our retail distribution of INJEX(TM) in the U.S. diabetes market,'' said Dr. James Gavin, Chairman of Equidyne. ``Stop & Shop has superior brand-name recognition and is backed by one of the world's largest food retailers. We are pleased to add a company of this stature to our team of retail marketing partners.'' Under the agreement, Super Stop & Shop locations with retail pharmacies will stock the INJEX(TM) product line in their stores. The stores also will participate in a program to promote INJEX(TM) during National Diabetes Month. The stores will host approximately 20 Diabetes Awareness Programs on Saturdays in October and November in stores located in Massachusetts, Connecticut and Rhode Island. ``By making the INJEX(TM) Needle-Free Delivery System available at Stop & Shop Pharmacies, we will be providing our diabetes customers, who may be uncomfortable with needle injections of insulin, the opportunity to try this clinically proven product,'' stated Andy Olem, R.Ph., Diabetes Care Coordinator at Stop & Shop. As part of Stop & Shop's continuing efforts to support people with diabetes, in-store programs such as diabetes food and pharmacy tours, diabetes alert day screenings and diabetes care days are offered regularly to educate people with diabetes on managing and controlling their disease. NOW IF PEOPLE WOULD ONLY HEAR ABOUT THE PRODUCT! We might have something going here! CC

To: dgrebles who wrote (159)	10/11/2001 7:03:51 PM
From: Skywatcher	Respond to of 179

OK...I email this letter to the company.... As a large stockholder it is great news that more companies are carrying the product. But there is NO public awareness of the existance of the product. WHY NOT SEND RUSH LIMBAUGH A FREE UNIT??????????? From a news article.... Doctors said they had seen some progress with the drugs, but not in the past week. <<<Limbaugh is injecting himself twice a week with part of the drug cocktail, which consists of two immunosuppressive drugs: prednisone and methotrexate, and a third drug known as embrel.>>>>> Although tests showed no recent improvement, doctors and Limbaugh himself cited what appeared to be visible signs of improvement during consultations on Wednesday. At this point ANYTHING would be nice.... Why not get LIBERTY on board...they have a celebrity spokesperson on the air EVERYDAY for diabetes MAIL ORDER! WILFORD BRIMLEY! Have you ever GIVEN HIM A FREE UNIT!?!? Please......Use your MARKETING BRAIN! Give the things away to those who can make others aware of the NEEDLELESS injection SYSTEM! CC

To: dgrebles who wrote (159)	10/16/2001 12:01:29 PM
From: Skywatcher	Respond to of 179

FINALLY a breakout from below a dollar!....and I wasn't shy about buying at .75 so I have successfully lowered the average per share price a LOT....Now for some real results. I understand that the company is doing a lot of workshops with CVC pharmacies in the East....getting the word out to the diabetics about the existance of an ALTERNATIVE to needles. We still need more than anything a BIG contract with a large pharma similar to the Abbott agreement with Westfield?...I think that is the name of the British company. CC

To: dgrebles who wrote (159)	10/30/2001 11:38:24 AM
From: Skywatcher	Read Replies (1) \| Respond to of 179

Net sales in the year ended July 31, 2001 were $247,000 as compared to $802,000 for the year ended July 31, 2000. Over the past two fiscal years, the Company divested its shares in Rosch AG, a German affiliate, through a series of private and public transactions. As a result, the Registrant received proceeds of $49.2 million and $14.3 million during the years ended July 31, 2001 and 2000, respectively. The net gains resulting from these transactions were $40.3 million and $12.7 million, in the years ended July 31, 2001 and 2000, respectively. Subject to the completion of the audit, the Company expects net income for the year ended July 31, 2001 to exceed $12.0 million, as compared to net income of $4.5 million for the year ended July 31, 2000. As of July 31, 2001, the Company has cash and shortterm investments of $22.6 million and working capital in excess of $18 million. This compares to cash and working capital of $2.0 million and $2.1 million, respectively as of July 31, 2000. In other news, the Company is implementing an 18person reduction in its sales force consistent with Equidyne's focus on clinical distribution, pharmaceutical licensing and consumer education in the domestic diabetes market. Dr. James Gavin, Chairman of Equidyne, commented that "we have found that consumer education for our needlefree products can be effectively accomplished with directtoconsumer advertising, an informative web site and sales support for our retail distribution partners including sales training and pointof sale materials. A substantial domestic sales organization for detailing doctors and hosting consumer seminars has not been found to be costeffective. Consequently, we are resizing our organization in accordance with our business strategy and our primary goal of achieving the fastest possible path to profitability. Undertaking this workforce reduction was difficult for everyone at Equidyne, but it is a necessary step given the current environment. We remain focused on developing and marketing needlefree drug delivery systems." The filing said that Equidyne had net sales of $247,000 in its fiscal year ended July 31, compared with $802,000 for the prior year. Over the past two fiscal years, Equidyne sold its shares in former German affiliate Rosch AG through a series of private and public transactions. As a result, Equidyne received proceeds of $49.2 million for the year ended July 31 and $14.3 million during the year ended July 31, 2000. The net gains resulting from these transactions were $40.3 million for the year ended July 31 and $12.7 million for the year ended July 31, 2000, the filing said. Net income for the year ended July 31 is expected to exceed $12 million, compared with $4.5 million the previous year. Was NOT hoping for a delay....I hope the $12 million figure is correct....worried that more loss of sales people will hurt the amount of sales. This makes it absolutely critical that a big pharma contract be WON! CC